<DOC>
	<DOC>NCT00708708</DOC>
	<brief_summary>This prospective observational cohort study will assess the average duration of the drug free interval between etanercept treatment cycles in usual care settings in Germany.</brief_summary>
	<brief_title>Observational Study Evaluating Etanercept (EnbrelÂ®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings</brief_title>
	<detailed_description>Non-interventional study: subjects to be selected according to the usual clinical practice of their physician</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subjects with moderate to severe plaque psoriasis on etanercept treatment according to the Summary of Product Characteristics (SmPC), and applicable local guidelines Subjects for whom the decision has already been made to initiate treatment with etanercept Sepsis or risk of sepsis Current or recent infections, including chronic or localized, e.g. tuberculosis (TB) infection Vaccination with live vaccine in last 4 weeks, or expected to require such vaccination during the course of the study Preexisting or recent onset CNS demyelinating disease. Class III or IV congestive heart failure as defined by the New York Heart Association classification or uncompensated congestive heart failure. Previous or ongoing treatment with etanercept Participation in other clinical or observational studies. Patients with psoriatic arthritis requiring continuous etanercept treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Plaque-type psoriasis</keyword>
</DOC>